CTLA4 and neoplasm: When combined with immune checkpoint inhibitors (anti–PD-1 and anti–CTLA-4), oral reovirus administration achieves complete tumor regression and establishes durable immune memory, highlighting its promise as a non-invasive immunotherapy [90].